8-(2-羟基苯甲酰胺基)辛酸钠
中文名称 | 8-(2-羟基苯甲酰胺基)辛酸钠 |
---|---|
中文同义词 | 8-(2-羟基苯甲酰胺基)辛酸钠;N-[8-(2-羟苯基)氨基]辛酸钠;SNAC,8-(2-羟基苯甲酰胺基)辛酸钠;N-[8-( 2-羟基苯甲酰基) 氨基] 辛酸钠;8-(2-羟基苯甲酰氨基)辛酸钠;8-水杨酰胺基辛酸钠;8-(2-羟基苯甲酰胺基)辛酸钠SNAC(索马鲁肽关键辅料);沙波立沙钠 |
英文名称 | Salcaprozate Sodium |
英文同义词 | SNAC,sodium 8-[(2-hydroxybenzoyl)amino]octanoate;Salcaprozate sodium;SODIUM 8-(2-HYDROXYBENZAMIDO)OCTANOATE (SNAC);Octanoic acid, 8-[(2-hydroxybenzoyl)amino]-, sodium salt;sodium,8-[(2-hydroxybenzoyl)amino]octanoate;sodium 8-(2-hydroxybenzamido)octanoate;Octanoic acid, 8-[(2-hydroxybenzoyl)amino]-, monosodium salt;SNAC |
CAS号 | 203787-91-1 |
分子式 | C15H22NNaO4 |
分子量 | 303.33 |
EINECS号 | 231-019-4 |
相关类别 | 阿司匹林衍生物;苯类;新冠疫苗辅料;小分子;API;SNAC;pharmaceutical |
Mol文件 | 203787-91-1.mol |
结构式 |
8-(2-羟基苯甲酰胺基)辛酸钠 性质
熔点 | 183 - 185°C |
---|---|
储存条件 | Inert atmosphere,Room Temperature |
溶解度 | 可溶于DMSO(少许)、甲醇(少许) |
形态 | 固体 |
颜色 | 白色至类白色 |
稳定性 | 吸湿性 |
InChI | InChI=1S/C15H21NO4.Na.H/c17-13-9-6-5-8-12(13)15(20)16-11-7-3-1-2-4-10-14(18)19;;/h5-6,8-9,17H,1-4,7,10-11H2,(H,16,20)(H,18,19);; |
InChIKey | OBKUJEVXEMKQMJ-UHFFFAOYSA-N |
SMILES | C(C1C=CC=CC=1O)(=O)NCCCCCCCC(=O)O.[NaH] |
8-(2-羟基苯甲酰胺基)辛酸钠,简称SNAC,是一种二碳磷酸盐化合物吸收促进剂,用于治疗胃肠道疾病,尤其适用于二碳磷酸盐化合物吸收不良引起的肠胃道疾病。
Salcaprozate sodium (SNAC) 是一种口服吸收促进剂,有潜力作为口服形式的肝素和胰岛素的递送剂。Salcaprozate sodium 可增加非共价大分子络合引起的亲脂性,从而增加小肠上皮细胞的被动跨细胞渗透。
SNAC (12.5-400 μg/mL; 24 h) has no toxicity to Caco-2 cells, and the survival percentage is above 90% when SNAC is 200 μg/mL.
SNAC (50 and 200 μg/mL) improves the apparent permeability coeffcient (Papp) of RA and SA-B by 2.14-fold and 3.68-fold compared with the Papp of SAs solution.
SNAC improves the oral absorption of both R1 and SAs and enhances bioavailability in rats.
SNAC (2000 mg/kg/d; oral gavage for 13 weeks) related mortality is evident only at the 2000-mg/kg/d level, 20% among males and 50% among females; no clear cause of death is evident.
SNAC (100-1000 mg/kg/d; oral gavage for 13 weeks) induces no mortality in the Wistar rat study at doses up to 1000 mg/kg/d.
Animal Model: | Sprague-Dawley rats (6-7 weeks) |
Dosage: | 2000 mg/kg/d |
Administration: | Oral gavage for 13 weeks |
Result: | Induced 20% and 50% mortality in males and females at the dose of 2000 mg/kg/d. |
安全信息
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/08/19 | XW0220378791106 | 8-(2-羟基苯甲酰胺基)辛酸钠,97% | 203787-91-1 | 25G | 1187元 |
2024/08/19 | HY-114299 | Salcaprozate sodium | 250 mg | 300元 |